Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
Status:
Terminated
Trial end date:
2020-09-08
Target enrollment:
Participant gender:
Summary
BGB-A333 is a humanized IgG1-variant monoclonal antibody against programmed cell death
1-ligand 1 (PD-L1), the ligand of an immune check point- receptor, programmed cell death-1
(PD-1). BGB-A317 is a humanized, IgG4-variant monoclonal antibody against PD-1. This study
tested the safety and anti-tumor effect of BGB-A333 alone and in combination with BGB-A317 in
participants with advanced solid tumors.